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Abstract  
The health burden of acute coronary syndrome (ACS) and frailty is high, but the 
impact of frailty on ACS treatment and outcomes is uncertain.  In this structured 
literature review, we investigated the relationship between frailty, ACS 
treatment and outcomes. Between 2000 and 2016, we identified only a small 
number of primary research studies investigating frailty and ACS care (n= 10).  
Frailty was independently associated with increased mortality following ACS 
(adjusted all-cause mortality hazard ratios for patients with frailty ranged from 
1.54 Ȃ 5.39). Older people with frailty were significantly less likely to receive 
guideline-indicated ACS care, including percutaneous coronary intervention 
(PCI) (Rates ranged from 6.7% -43.7% vs. 30.4%-69.5%). Available data for PCI 
indicated a gap between treatment recommended by international guidelines 
and clinical practice. Further research is warranted to investigate methods for 
identifying frailty in the acute setting and opportunities for improving care 
among older people with frailty presenting with ACS.   
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Introduction 
 
Over half of all people admitted to hospital with acute coronary syndrome (ACS) 
are elderly and many have substantial multi-morbidity. 1 Moreover, about 10% 
of those over the age of 65 years and 25-50% of those over the age of 
85 years are considered frail.2, 3  
 
 
Definition of frailty 
 
Frailty is a condition characterised by loss of biological reserves, which leads to 
failure of homeostatic mechanisms following stressor events .4 An acute 
myocardial infarction is an example of a stressor event from which an older 
person with frailty may be at greater risk of adverse outcomes, compared to a fit 
older person. 
 
Frailty is best understood as a long-term condition but it is especially 
problematic because it often remains invisible to health and care services until 
revealed by an unforeseen event.  In addition, the severity of frailty at an 
individual level is important because it is a more reliable predictor for adverse 
outcomes than chronological age.5, 6 Therefore, UK and international guidelines 
have recommended routine identification of frailty as part of clinical 
encounters,7, 8 but this has not yet become embedded as part of routine clinical 
care, including in the context of acute coronary syndrome. 
 
Frailty models 
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The phenotype model9 and the cumulative deficit model10  are the two best-
established international frailty models. Both have been extensively validated in 
large epidemiological studies, but are less practical for use in day-to-day clinical 
practice. The phenotype model identifies frailty on the basis of five physical 
characteristics: weight loss; exhaustion; low energy expenditure; slow gait 
speed; and reduced grip strength. People with no characteristics are identified as 
fit; those with one or two identified as pre-frail; those with three or more are 
identified as frail. The cumulative deficit model identifies frailty on the basis of a 
range of 'deficits', which can be clinical signs, symptoms, diseases and 
disabilities. A frailty index (FI) score is calculated as a proportion of the number 
of deficits present to the total possible in the model (e.g. if 9/36 deficits are 
present, the FI score = 0.25). The model is useful as it is very flexible - it has been 
established that a minimum of 30 deficits are required for a model to be valid. 
 
Simple frailty tools and questionnaires 
A range of simple frailty tools and questionnaires are available and validated for 
use in clinical practice.11 The 2016 UK National Institute for Health and Care 
Excellence (NICE) multimorbidity guideline12 recommends using one of: gait 
speed <0.8 m/s; timed up and go test score <12 seconds; self-reported health 
status score <6; PRISMA-7 questionnaire > 3; self-reported physical activity scale 
in the elderly (PASE) score <56 for men or < 59 for women to identify the 
presence of frailty. The NICE guideline cautions against using a performance-
based tool in people who are acutely unwell because frailty and acute illness can 
be conflated using, for example, gait speed. However, the Clinical Frailty Scale10 
and Reported Edmonton Frail Scale13 have been validated for use in secondary 
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care, and are potentially useful for inpatient cardiology care. More recently, an 
electronic frailty index (eFI) has been developed and validated using routine 
electronic health record data, which is supported in NICE guidance, and may 
have future application to identify frailty in the context of ACS.11 
 
Frailty and ACS 
Although there are well defined pathways for the management of ACS (based 
upon class 1 guideline recommendations), these have predominantly been based 
on randomised controlled trial evidence that is not necessarily generalisable to 
older people with frailty.  Existing evidence indicates adherence to guideline 
recommendations for the management of ACS is suboptimal in both older people 
and those with multi-morbidity, and resultant outcomes are poor.1, 14, 15 Yet, what 
is unknown is how frailty interplays with the provision of treatments and 
subsequent clinical outcomes among patients with ACS. Indeed, to date there is 
no international consensus as to how patients with frailty and ACS should be 
managed.  Development of new models of ACS care for older people based on 
individual frailty should be informed by robust research evidence. 
 
No previous reviews have explored the relationship between frailty, quality of 
treatment and outcomes in older people who experience ACS. We therefore 
undertook a structured literature review of observational studies and 
randomised controlled trials to investigate the relationship between frailty, ACS 
treatment and outcomes. 
 
Methods 
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We followed the PRISMA guidelines to undertake a structured literature review.  
A Medline search strategy was developed and adapted for CINAHL, EMBASE, 
Web of Science and AMED. All databases were searched from 1st January, 2000 
to the 26th September, 2016. The search was restricted to English language 
publications.  The full search strategy is available in Appendix 1.  
 
Eligibility Criteria 
Eligible studies were those using a validated model to assess frailty in patients 
during their admission with ACS, defined as AMI (either ST-segment elevation, 
STEMI, or non-ST-segment elevation myocardial infarction, NSTEMI) and 
unstable angina. All abstracts were reviewed by two reviewers (OB, FS) and 
potentially eligible studies retrieved. These articles were reviewed in full against 
the stated eligibility criteria and reference lists were searched to identify 
additional articles. 
 
Results 
The search strategy identified 980 papers (Figure 1). Of these, 83 were retrieved 
for detailed evaluation and ten were considered eligible for inclusion based on 
the stated eligibility criteria.16-25 Three papers studied frailty in a percutaneous 
coronary intervention (PCI) population that contained both ACS and stable 
angina patients and were, therefore, not included in the main review.26-28 There 
was one sub-study of the TRIUMPH registry which assessed gait speed one 
month after an AMI this was not included as the frailty assessment occurred one 
month after the index event.29 
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The ten included papers reported data from a total of 8,773 patients 
participating in nine individual cohort studies and one randomised controlled 
trial (RCT).16-25 Two papers reported data from one cohort investigating 30 day 
and one year mortality.16, 17  
 
Definition of frailty 
The studies defined frailty and pre-frailty using a range of validated tools. Two 
used the phenotype model, or its modified version.24, 25 Four used the Canadian 
Study of Health and Ageing Clinical Frailty Scale.16, 17, 19, 22 One applied the 
Edmonton Frail Scale;18  one used the Tilburg Frailty index;20 one used gait 
speed;21 one used the SHARE-FI index23 (which has been validated in the 
primary care setting) and one used the Green score, which is a validated frailty 
tool including measures of grip strength, gait speed and activities of daily 
living.24 (Supplementary table 1) 
 
Patient population 
The papers reported on a range of patient populations. Four papers reported on 
AMI.16, 17, 21, 22 Two studied whether patients with NSTEMI had the opportunity to 
receive all appropriate therapies.16, 17 One studied patients with non ST-elevation 
acute coronary syndrome (NSTEACS) who only received medical management.25 
One considered patients with STEMI.21 Six studied patients following 
hospitalisation with ACS.18-20, 23-25 Table 1 reports the main study characteristics 
and outcome measures.  
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Five studies reported higher prevalence of frailty amongst female patients16-18, 22, 
25, and three demonstrated higher prevalence in men.19, 21, 24 However, none of 
the differences were statistically significant. Frail participants were typically 
older (74.6 years) than non-frail participants (mean age 69.8 years). 16, 17, 22, 25   
 
Prevalence of frailty 
The median reported prevalence of frailty across the studies was 31.5% (range 
4.7% to 82.4%).20, 25 The median reported prevalence of pre-frailty was 35.4% 
(range 23.0% to 36.6%).18, 25 The lowest prevalence was seen in the TRILOGY 
ACS randomised controlled trial, at 4.7% for frailty and 23.0% for pre-frailty, 
defined using the phenotype model.25 
 
Mortality 
Nine manuscripts described a statistically significantly higher mortality rate in 
participants with frailty compared to those defined as non-frail.16-19, 21-25 One 
manuscript did not report mortality.20 Mortality was measured at a variety of 
points from in hospital23 to 13 years (Table 2).22 Mortality was adjusted for age, 
sex and clinical variables. Several studies employed the coronary artery disease 
(CAD) specific index as a measure of comorbidity, which includes current 
smoker, hypertension, and history of cerebrovascular disease, diabetes, chronic 
obstructive pulmonary disease, peripheral vascular disease, malignancy, and 
chronic kidney disease. Three studies reported cardiovascular mortality in 
addition to all-cause mortality. All showed higher rates in older people with 
frailty compared with those who were not frail.21, 22, 25 One study reported that 
faster walking speed, used to identify fit older people, was independently 
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associated with reduced mortality. For every 0.1m/s increment in gait speed 
significant reductions in all-cause mortality (HR 0.71, 95% CI 0.62 to 0.82) and 
cardiovascular mortality (HR 0.65, 95% CI 0.55 to 0.81) were observed. 
 
Invasive Coronary Procedures 
Seven papers reported the use of invasive coronary procedures among 
participants with frailty, and those defined as non-frail. 16-19, 21, 23, 25  
 
Coronary angiography 
Six papers reported on coronary angiography. When the populations were 
subdivided, the rates of angiography among participants defined as frail and 
non-frail were 75.7% vs. 85.0% (P=0.027),19 15.4% vs. 46.2% (P<0.001),16, 17 
66.2% vs. 93.1% (P<0.001),23 and 58.2% vs. 88.9% (P<0.001).18 The one 
randomised controlled trial found no statistically significant difference in the 
rate of angiography pre- or post-randomisation to either clopidogrel or 
prasugrel; rates of angiography were 53.2% for those with frailty; 45.9% for 
those with pre-frailty; 48.2% for those with no frailty.25  
 
One study considered the characteristics of those frail patients who received 
angiography against those who did not. The only statistically significant variable  
was age (mean age 86 vs. 80 years, P<0.001), however, in general those who 
received angiography were younger, more likely to be male and less likely to 
have dementia, congestive heart failure or severe renal disease 
(GFR<30ml/min).16 
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Percutaneous coronary intervention 
Three papers investigating use of PCI in older people following ACS reported 
rates of 6.7 vs. 30.4%,16 16.4 vs. 36.5%,18 and 43.7% vs. 69.5%23 in frail and non-
frail patients respectively. One manuscript investigated the use of coronary 
artery stent implantation in those receiving PCI and reported a non-statistically 
significant decrease in use for those with frailty compared with non-frail patients 
(67.1% vs. 69.7%, P=0.83).21 One study suggested that frail patients were less 
likely to receive complete revascularisation than their non-frail counterparts 
(28.2% vs. 46.6%, P<0.001).23 In another study, of whom 82.4% were reported 
to be frail, receipt of PCI was associated with a better quality of life than those 
who were managed conservatively (P=0.043).20 
 
Coronary artery bypass grafting 
One paper offered details about coronary artery bypass grafting rates and found 
no significant difference in rates of coronary artery bypass grafting among 
participants with frailty (9.1% vs. 12.7%, P=0.364).18  
  
Pharmacological management 
Two articles investigated pharmacological management among frail older people 
with ACS. The first a sub study of the Trilogy-ACS trial which compared the use 
of prasugrel with clopidogrel, compared medication management by frailty 
status; this was only studied at point of randomisation (patients assigned to 
either clopidogrel or prasugrel) and not at hospital discharge. All patients in this 
study received medical management. Increasing frailty was associated with a 
decrease in use of statins (P=0.011) and angiotensin converting enzyme 
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inhibitors (ACEi) or angiotensin II receptor blockers (ARB) (P<0.001). There was 
no Ⱦ-blockers between frail and non-
frail patients (P=0.141). People with frailty were less likely to receive proton 
pump inhibitors (P=0.009).25 Older people with frailty randomised to prasugrel 
experienced lower rates of the composite endpoint of cardiovascular death, MI 
or stroke, and lower all-cause mortality than those randomised to clopidogrel. 
However, older people with frailty were more likely to have bleeding events on 
prasugrel, compared with clopidogrel.25 
 
The other study found that the prescription of medications at discharge from 
hospital did not vary across tertiles of gait speed.21 Those with slower gait 
speeds were less likely to be prescribed an ACEi/ARB (P=0.001) and statins 
(P=0.003), though there was no statistically significant difference in prescription Ⱦ-blockers (P=0.18). The study reported additional characteristics of those 
who were not prescribed ACEi/ARB and statins. Participants who did not receive 
these medications were older, had reduced renal function and lower levels of 
low-density lipoproteins (LDL).21 Neither study demonstrated a difference in the 
rate of prescription of aspirin for frail and non-frail patients.  
 
Hospital stay 
Four studies provided information on where patients received their treatment.16, 
17, 19, 22 Three identified that older people with frailty were less likely to receive 
treatment in an intensive cardiac unit,16, 17, 22 whilst one reported that frail 
patients were more likely to be cared for in an intensive cardiac unit than non-
frail (32.9% vs. 20.5% P=0.009).19 
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Three studies reported that frail patients had longer length of stay, compared to 
non-frail patients (13.4 vs. 7.5 bed days, P<0.00116, 17 and 12.7 vs. 7.0 bed days, 
P=0.03018). Whilst another study found no statistically significant difference in 
lengths of hospital stay between the frail and non-frail  (6.8 vs. 10.0 bed days, 
P=0.666).23 
 
Re-admission 
Four papers provided information on unplanned re-admissions.16, 17, 19, 22  
One study reported no statistically significant difference in readmission for 
people with frailty compared to fit older people at either one month (29.9% vs. 
21.9%, P=0.138) or 12 months (61.7% vs. 67.7%, P=0.28).16 17 One demonstrated 
a statistically significant increase in readmission (12.0% vs. 32.2% P<0.001).19 
Another study with 5.5 year follow-up data reported higher rates of re-
admission among older people with frailty compared with those who were not 
frail (rate ratio of 3.31, 95% CI 2.57-4.27); an effect which persisted after 
adjustment for age, sex, clinical and socioeconomic variables (adjusted rate ratio 
2.14, 95% CI 1.63-2.81).22 Two studies provided information on the reasons for 
readmission. A cardiovascular cause was identified in 14% and 50% of patients 
in these studies, respectively.17, 19 
 
Quality of life 
One study Ǯǯ (as 
assessed by the MacNEW Heart disease Health related Quality of Life 
questionnaire) it was completed prior to discharge from hospital, the authors 
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demonstrated a negative correlation between frailty and quality of life in 
patients experiencing an ACS.20  
 
Discussion 
Our review has identified that frailty and pre-frailty are common in older people 
experiencing ACS, with a median prevalence estimate of 31.5% for frailty and 
35.4% for pre-frailty across included studies. We have also summarised evidence 
indicating that the presence of frailty and pre-frailty identifies patients at 
increased risk of mortality following admission to hospital with ACS. 
 
A range of validated frailty assessment tools were used in the studies. Although 
clinicians might wish to select tools to align with local service requirements, we 
recommend the Clinical Frailty Scale as a tool that is practical, validated in a 
secondary care setting, identified as the most commonly applied standardised 
frailty assessment in an ACS research context, and is predictive of adverse ACS 
outcomes. Alternative simple tools, such as gait speed, might be considered for 
ACS patients who are ambulant, or as part of an outpatient workup. The eFI is a 
frailty identification tool that has been developed using routine data.11 It has 
been widely implemented in the UK but is based on international standard 
coding systems, so has potential for future global implementation, depending on 
future validation. 
 
Despite evidence for increased risk of mortality, rates of coronary angiography 
and PCI among older people with frailty are low. There was no evidence to 
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indicate differences in use of aspirin or Ⱦ-blockers for those with frailty, but 
evidence indicates lower rates of ACEi, ARB and statin prescription. 
 
Previous research has demonstrated improved outcomes for those invasively 
managed following ACS.15 Our review has identified that people with frailty were 
less likely to receive an invasive coronary strategy.16, 18, 25 One RCT reported 
similar rates of PCI for those with frailty, pre-frailty and no frailty, but 
prevalence estimates for frailty in this study were low, indicating that the study 
population may not be representative. Furthermore, the tightly controlled RCT 
environment may have precluded deviation from the trial protocol for 
participants based on clinical judgment regarding suitability for PCI, limiting 
generalisability of findings to routine clinical practice. 
 
People with frailty who received coronary angiography had lower 
revascularisation rates than less frail counterparts. 16, 18, 23 This may be, in part, a 
reflection of the more complex coronary artery disease identified in those with 
frailty, who were more likely to have left main stem disease, three vessel disease 
or proximal disease, which may not be amenable to PCI.27, 28 However, it is also 
possible that lower rates reflect an aversion to a perceived risk of invasive 
management in frailty, whereby those with potential to gain benefit may have 
been deemed not appropriate for coronary intervention. 
 
The review has identified a possible difference in rates of management on 
intensive cardiac units depending on individual frailty. Three studies recorded 
lower rates of admission to intensive cardiac units16, 17, 22 whilst one 
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demonstrated higher rates of admission to such units for people with frailty.19 
Those which showed a negative association with frailty were conducted in 1992-
9322 and 2009-10,16, 17 whilst the one with a positive association was conducted 
in 2014-15.19 It is possible that the differences observed may be due in part to 
the increasingly frail hospital demographic in modern healthcare systems, but 
also may indicate potential changes in recognition and understanding of frailty 
amongst clinicians over this time period. 
 
Evidence from this review indicates that older people with frailty have a longer 
length of hospital stay, and that there is uncertainty regarding the association 
between frailty and rehospitalisation following ACS; rates vary between 14% 
and 50% for cardiovascular-related readmissions. 
 
There was also a paucity of information on medication management for those 
with frailty and ACS. The two available studies identified lower rates of ACEi, 
ARB and statin prescribing following ACS. Prescribing decisions are especially 
complex for those with frailty, who are at increased risk of medication-related 
side effects. Careful clinical judgment is required to weigh up the compromise 
between risk of harm due to side effects and longer-term benefit based on likely 
duration of treatment.21 Some older people with advanced frailty may be 
entering the terminal phase of life, and a decision to withhold a medication that 
may not provide overall benefit and may increase polypharmacy burden and risk 
of side effects may be considered appropriate.  
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The 2016 NICE multimorbidity guideline includes a database of treatment effects 
summarising the benefits/harms of a range of medications in multimorbid 
patients. 30 In addition to standard numbers needed to treat (NNTs) the database 
includes additional information on treatment time horizon, which enables 
calculation of annualised numbers needed to treat (ANNTs), which is the number 
of people requiring treatment per year to receive benefit. ANNT estimates are 
especially helpful for making judicious treatment decisions for older people with 
advancing frailty, some of whom may be in the terminal stage of life. Treating 
1000 people with statins for one year would result in four fewer cardiovascular 
deaths.30 
 
Lower levels of provision of ACS care may be the result of a lack of randomised 
evidence to guide ACS management in the context of frailty. We identified only 
one RCT that used a validated tool to assess frailty. Within this study, prevalence 
of frailty was notably low at 4.7%, compared to our median prevalence estimate 
across studies of 38.1%.25 In this trial, rates of cardiovascular and all-cause 
mortality for people with frailty were lower than reported in observational 
studies. This may be because the trial participants did not include people with 
advanced frailty in the terminal phase of life, which would be consistent with the 
relatively low study prevalence of frailty. The study did show that frail patients 
benefited more with respect to outcomes if they received prasugrel, however, 
this group had higher rates of bleeding complications. The bleeding 
complications may in part be due to a lower use of proton pump inhibitors in the 
frail group.25 
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Only one study assessed quality of life outcomes showing that those with frailty 
have worse quality of life outcomes than those without frailty. This is supported 
by a study of a mixed population of ACS and stable angina patients reporting 
health-related quality of life in participants immediately after PCI using the 
Short-Form 36 item health questionnaire (SF36) and quality of life scale of the 
Seattle Angina Questionnaire (SAQ). Those with frailty had lower physical and 
mental health-related quality of life summary scores on the SF36 (P<0.001) and 
lower SAQ quality of life scores (P=0.013), compared with those defined as fit.26 
Greater consideration of non-mortality driven outcomes, such as morbidity, 
healthcare utilisation and quality of life are desirable when assessing the efficacy 
of ACS interventions among this group.  
 
To our knowledge, this is the first review reporting international data about the 
prevalence, management and outcomes of ACS in older people with well-defined 
frailty. The review was supported by a robust search strategy that has enabled a 
comprehensive review of the available literature. We only included data from 
studies that used a validated tool to identify frailty in participants and had full 
text available for assessment. An important limitation of this review is that 
ambiguity remains regarding whether the association between frailty and 
mortality represents the loss of biological reserves associated with the condition, 
or is the result of under treatment of this high-risk group. Furthermore, we 
excluded three studies that investigated outcomes of PCI in mixed ACS and stable 
angina populations but did not report results by subgroup. These studies 
reported no clear difference in mortality at 30 days between those with frailty 
undergoing PCI for ACS or stable angina, compared to those without.26 Three-
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year rates of MI or mortality for those with frailty were higher, but increased 
mortality rates in people with frailty at more distant time points are not 
necessarily unexpected, and cannot be reliably associated with PCI treatment.27 
The investigation of outcomes of PCI in frail and non-frail older people with ACS 
is an important area for future investigation because, should similar outcomes be 
confirmed, this may indicate that the higher mortality following ACS for older 
people with frailty is potentially modifiable through appropriate treatment.  We 
also excluded a study that performed frailty assessments one month after the 
index event; they demonstrated that slow gait speed (<0.8m/s) was present in 
53.6% of patients and that those with slow gait speed had worse outcomes 
(including mortality and readmission) at one year. However, they did note that 
readmission was the predominant driver of their composite endpoint and that 
only 41.9% of the readmissions in the slow gait speed group were for a 
cardiovascular cause.29 
 
Future challenges 
Presently, there is only preliminary evidence to guide decision making in the 
management of frail patients with ACS, and establishment of a more robust 
evidence base is required. The under-representation of older people with frailty 
in RCTs of ACS interventions risks excluding those at greatest risk of adverse 
outcomes following ACS and limits the generalisability of trial findings. The one 
RCT that was included in the review reported similar drop-out rates for patients 
with both frailty and pre-frailty, but these groups demonstrated significantly 
higher drop-out rates than the non-frail group. These estimates should be 
considered when designing future RCTs of ACS interventions involving people 
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with frailty. Within the UK, the RINCAL study aims to look at revascularisation 
versus a conservative strategy in patients >80, although there it is unclear 
whether there will be a frailty assessment involved within the study.31 The 
ICON1 study is a prospective observational study that follows patients with 
NSTEMI >75 years, which utilises both the phenotype model and cumulative 
deficit frailty index to assess frailty.32 The Italian STORM study used the Gold 
standards framework (GSF) as a surrogate for frailty and similarly to our study 
found a reduction in the rates of PCI. Use of the GRACE risk score (as per existing 
guidelines33, 34) was determined to be accurate at predicting cardiovascular 
events, however did not predict death from other causes.35  
 
Design of future RCTs of ACS interventions should include methods to select and 
stratify participants on the basis of individual frailty to help guide appropriate 
decision-making based on an individual balance of risk and benefit. Resultant 
evidence can then contribute to the development of clinical guidelines for ACS 
management that consider the complex challenges that are commonly 
encountered by clinicians caring for older people with frailty. 
 
Conclusion 
This structured review found that of the limited studies to date, nearly a third of 
older people presenting to hospital with ACS are to be frail or pre-frail. These 
people, at increased risk of mortality following ACS, are less likely to receive an 
invasive coronary strategy and pharmacological therapies.  To inform new 
models of ACS care that consider individual frailty, research investigating the 
association between frailty, coronary interventions, pharmacological therapy 
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and outcomes will be necessary. In addition, there is a need for a frailty 
assessment tool for cardiovascular patients that can be used in the acute setting 
to help guide appropriate care to achieve optimal patient-centred outcomes.  
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